Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2026)
Royalty Pharma (RPRX) posted Accumulated Expenses of $25.3 million for Q1 2026, down 77.17% sequentially from $110.8 million in Q4 2025, and up 31.64% YoY from $19.2 million in Q1 2025.
Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2026) Analysis & Trends
Royalty Pharma has reported Accumulated Expenses for 7 years, with the latest figure at $25.3 million in Q1 2026.
- Quarterly Accumulated Expenses rose 31.64% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.3 million (up 31.64% YoY) and the FY2025 annual result came in at $110.8 million, up 13.01% from the prior year.
- Accumulated Expenses slipped to $25.3 million in Q1 2026 per RPRX's latest filing, from $110.8 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $110.8 million in Q4 2025 and troughed at $12.6 million in Q3 2023.
- A 5-year average of $43.6 million and a median of $38.4 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 204.98% in 2024, then slipped 24.39% in 2025.
- Over 5 years, Accumulated Expenses stood at $54.2 million in 2022, then retreated by 4.58% to $51.7 million in 2023, then surged by 89.74% to $98.1 million in 2024, then increased by 13.01% to $110.8 million in 2025, then tumbled by 77.17% to $25.3 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $25.3 million, $110.8 million, and $29.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107.77 Mn |
| Mar 31, 2026 | 25.30 Mn |
| Dec 31, 2025 | 110.82 Mn |
| Sep 30, 2025 | 29.04 Mn |
| Jun 30, 2025 | 85.61 Mn |
| Mar 31, 2025 | 19.22 Mn |
| Dec 31, 2024 | 98.06 Mn |
| Sep 30, 2024 | 38.41 Mn |
| Jun 30, 2024 | 56.25 Mn |
| Mar 31, 2024 | 12.60 Mn |
| Dec 31, 2023 | 51.68 Mn |
| Sep 30, 2023 | 12.60 Mn |
| Jun 30, 2023 | 54.16 Mn |
| Mar 31, 2023 | 13.20 Mn |
| Dec 31, 2022 | 54.16 Mn |
| Sep 30, 2022 | 13.20 Mn |
| Jun 30, 2022 | 54.16 Mn |
| Mar 31, 2022 | 13.20 Mn |
| Dec 31, 2021 | 57.70 Mn |
| Sep 30, 2021 | 16.73 Mn |